DP-303c

DB17212InvestigationalProtein Based Therapies

DP-303c: Overview.

Mechanism: Pharmacologically active on Receptor tyrosine-protein kinase erbB-2
Curator reviewed
Also known as: ADC DP303c · antibody-drug conjugate DP303c
Code names: DP 303c

Resolves to

Compound

Targets

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with DP-303c, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.